Gatipotuzumab

Gatipotuzumab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.^[1] Gatipotuzumab is being developed by Glycotope GMBH ^[2] and is undergoing a phase II clinical trial for ovarian cancer.^[3]

Gatipotuzumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	tumor specific glycosylation of MUC1
Clinical data
Other names	PankoMab-GEX, anti-TA-MUC1
ATC code	None
Identifiers
CAS Number	1264737-26-9 Y
ChemSpider	none
UNII	85V55ZLV2Z